Role of TNF in lymphocyte-mediated cytotoxicity

Microscopy Research and Technique

Volumn 50, Issue 3, 2000, Pages 196-208

  Smyth, Mark J ^a   Johnstone, Ricky W ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Cell death; Cytotoxicity; Lymphocyte; Natural killer; Tumor necrosis factor; Virus

Indexed keywords

CELL DEATH; GLYCOPROTEINS; LIGANDS; LYMPHOCYTES; MACROPHAGES; TUMORS; VIRUSES;

CELLULAR DIFFERENTIATION; INTRACELLULAR PATHOGENS; KNOW-THAT; LYMPHOID TISSUE; NATURAL KILLER; PATHOLOGICAL CONDITIONS; PHYSIOLOGICAL CONDITION; SECONDARY LYMPHOID TISSUE; TISSUE STRUCTURE; TUMOR NECROSIS FACTORS;

CYTOTOXICITY;

ENDOTOXIN; LIGAND; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL SURVIVAL; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; T LYMPHOCYTE;

EID: 0034254454     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20000801)50:3<196::AID-JEMT3>3.0.CO;2-9     Document Type: Article

References (155)

1. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K, Imawari M. 1997. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 158: 5283-5291.
2. Arch RH, Gedrich RW, Thompson CB. 1998 Tumor necrosis factor receptor-associated factors (TRAFs), a family of adaptor proteins that regulate life and death. Genes Dev 12:2821-2830.
3. Armitage RJ. 1994. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6:407-413.
4. Asselin-Paturel C, Pardoux C, Gay F, Chouaib S.1998. Failure of TGFβ1 and IL-12 to regulate human FasL and mTNF alloreactive cytotoxic T-cell pathways. Tissue Antigens 51:242-249.
5. Baker SJ, Reddy EP. 1998. Modulation of life and death by the TNF receptor superfamily. Oncogene 17:3261-3270.
6. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: implications for TNF receptor activation. Cell 73:431-445.
7. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, Varmuza S, Latham KE, Flaws JA, Salter JC, Hara H, Moskowitz MA, Li E, Greenberg A, Tilly JL, Yuan J. 1998. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 12:1304-1314.
8. Beutler B. 1990. TNF in pathophysiology: biosynthetic regulation. J Invest Dermatol 95:81S-84S.
9. Beutler B, van Huflel C. 1994. Unraveling function in the TNF ligand and receptor families. Science 264:667-668.
10. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729-733.
11. Bodmer J-L, Burns K, Schneider P, Hofmann K, Steiner V, Thome M, Bornand T, Hahne M, Schroter M, Becker K, Wilson A, French LE, Browning JL, MacDonald HR, Tschopp J. 1997. TRAMP, a novel apoptosis mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (APO-1, CD95). Immunity 6:79-88.
12. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 85:803-815.
13. Bradley M, Zeytun A, Rafi-Janajreh A, Nagarkatti PS, Nagarkatti M. 1998. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas' and Fas-tumor cells. Blood 92:4248-4255.
14. Carlberg AL, Moberg KH, Hall DJ. 1999. Tumor necrosis factor and gamma-interferon repress transcription from the c-myc P2 promoter by reducing E2F binding activity. Int J Oncol15:121-126.
15. Castedo M, Macho A, Zamzami N, Hirsch T, Marchetti P, Uriel J, Kroemer G. 1995. Mitochondrial perturbations define lymphocytes undergoing apoptotic deletion in vivo. Eur J Immunol 25:3277-3284.
16. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505-512.
17. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, Dixit VM. 1996. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 271:4961-4965.
18. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. 1997. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis C-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 94:10057-10062.
19. Cohen PL, Eisenberg RA. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-269.
20. Combadiere B, Reis e Sousa C, Trageser C, Zheng LX, Kim CR, Lenardo MJ. 1998. Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo. Immunity 9:305-313.
21. Decker T, Lohmann-Matthes ML, Gifford GE. 1987. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138:957-962.
22. Degli-Esposti M. 1999. To die or not to die: the quest of the TRAIL receptors. J Leukoc Biol 65:535-542.
23. Deveraux QL, Reed JC. 1999. IAP family proteins: suppressors of apoptosis. Genes Dev 13:239-252.
24. Dick T, Reichmann G, Ebnet K, Simon MM, Dienes HP, Echternacher B, Krammer PH, Reske-Kunz AB. 1993. An ovalbumin peptide-specific cytotoxic T cell clone with antigen self-presentation capacity uses two distinct mechanisms to kill target cells. Cell Immunol 152:333-347.
25. Dimitrov T, Krajcsi P, Hermiston TW, Tollefson AE, Hannink M, Wold WS. 1997. Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J Virol 71:2830-2837.
26. Duan H, Dixit VM. 1997. RAIDD is a new 'death' adaptor molecule. Nature 385:86-89.
27. Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KC, Schreiber RD, Goeddel DV, Moore MW. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560-563.
28. Foghsgaard L, Jaattela M. 1997. The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type. J Virol 71:7509-7517.
29. + cytotoxic T-lymphocyte clones. J Virol 73:3623-3629.
30. Goltsev YV, Kavalenko AV, Arnold E, Varfolomeev EE, Brodianski VM, Wallach D. 1997. CASH, a novel caspase homologue with death effector domains. J Biol Chem 272:19641-19644.
31. Gooding LR. 1992. Virus proteins that counteract host immune defenses. Cell 71:5-7.
32. Goossens V, Grooten J, De Vos K, Fiers W. 1995. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 92:8115-8119.
33. Gorelik L, Rubin M, Prokhorova A, Mokyr MB. 1995. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J Immunol 154:3941-3951.
34. Gorelik L, Bar-Dagan Y, Mokyr MB. 1996. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J Immunol 156:4298-4308.
35. Gotoh Y, Cooper JA. 1998. Reactive oxygen species-and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-α signal transduction. J Biol Chem 273:17477-17482.
36. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802.
37. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. 1998. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28:257-263.
38. Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A. 1999. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 8:3034-3043.
39. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. 1994. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 91:3764-3768.
40. Haas E, Grell M, Wajant H, Scheurich P. 1999. Continuous autotropic signaling by membrane-expressed tumor necrosis factor. J Biol Chem 274:18107-18112.
41. + T cells. J Exp Med 186:1407-1418.
42. Hampton MB, Orrenius S. 1997. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 414: 552-556.
43. Hawkins CJ, Ekert PG, Uren AG, Holmgreen SP, Vaux DL. 1998. Anti-apoptotic potential of insect cellular and viral IAPs in mammalian cells. Cell Death Differ 5:569-576.
44. Heller RA, Song K, Fan N, Chang DJ. 1992. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70:47-56.
45. Heller R, Kronke M. 1994. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 126:5-9.
46. Hess S, Engelmann H. 1996. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 183:159-167.
47. Hildeman DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, Marrack PC. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10:735-744.
48. Hsu H, Xiong J, Goeddel DV. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81:495-504.
49. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387-396.
50. Hu S, Vincenz C, Buller M, Dixit VM. 1997. A novel family of viral death effector domain-containing molecules that inhibit both CD-95-and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem 272:9621-9624.
51. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. 1996. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 384:638-641.
52. Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB, Freedman RS. 1992. Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes. Cancer Immunol Immunother 35:83-91.
53. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195.
54. + T cells. Transplantation 68:97-100.
55. Jewett A, Bonavida B. 1996. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol156: 907-915.
56. Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, Ashkenazi A, Espevik T. 1999. Regulation of Apo-2 ligand/TRAIL expression in NK cells - involvement in NK cell-mediated cytotoxicity. Cytokine 11:664-672.
57. Jongeneel CV, Nedospasov SA, Plaetinck G, Naquet P, Cerottini JC. 1988. Expression of the tumor necrosis factor locus is not necessary for the cytolytic activity of T lymphocytes. J Immunol 140:1916-1922.
58. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. 1994a. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
59. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. 1994b. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530.
60. Kawanishi M. 1997. Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor alpha and anti-Fas antibody. J Virol 71:3319-3322.
61. + T cell-mediated cytotoxicity. J Immunol 162:2639-2647.
62. Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, Okamura H, Nakanishi K, Okumura K, Yagita H. 1999b. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 163:1906-1913.
63. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. 1998. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8:297-303.
64. Kettle S, Alcami A, Khanna A, Ehret R, Jassoy C, Smith GL. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β-converting enzyme and protects virus-infected cells from TNF-and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J Gen Virol 78:677-685.
65. Kinkhabwala M, Sehajpal P, Skolnik E, et al. 1990. A novel addition to the T cell repertory. Cell surface expression of tumour necrosis factor/cachectin by activated normal human T cells. J Exp Med 171:941-946.
66. Korner H, Cretney E, Wilhelm P, Kelly JM, Rollinghoff M, Sedgwick JD, Smyth MJ. 2000. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med 191: 89-96.
67. Krajcsi P, Wold WS. 1998. Inhibition of tumor necrosis factor and interferon triggered responses by DNA viruses. Semin Cell Dev Biol 9:351-358.
68. Kuhweide R, Van Damme J, Ceuppens JL. 1990. Tumor necrosis factor-alpha and interleukin 6 synergistically induce T cell growth. Eur J Immunol 20:1019-1025.
69. Lahn M, Kalataradi H, Mittelstadt P, Pflum E, Vollmer M, Cady C, Mukasa A, Vella AT, Ikle D, Harbeck R, O'Brien R, Born W. 1998. Early preferential stimulation of gamma delta T cells by TNF-α J Immunol 160:5221-5230.
70. Laster SM, Wood JG, Gooding LR. 1988. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 141:2629-2634.
71. Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER. 1996. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157: 1919-1925.
72. Lee SY, Park CG, Choi Y. 1996. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 183:669-674.
73. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. 1997. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 7:703-713.
74. Le Guiner S, Le Drean E, Labarriere N, Fonteneau JF, Viret C, Diez E, Jotereau F. 1998. LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal. Eur J Immunol 28:1322-1331.
75. Le Hir M, Bluethmann H, Kosco-Vilbois MH, Muller M, di Padova F, Moore M, Ryffel B, Eugster HP. 1996. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med183:2367-2372.
76. Li H, Zhu H, Xu CJ, Yuan J. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501.
77. + T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-α: relative insensitivity to Fas ligand. Am J Respir Cell Mol Biol 20:849-858.
78. + cytolytic T lymphocyte clones. Evidence for a TNF-α-independent cytolytic mechanism. J Immunol 148:3789-3798.
79. Liu ZG, Hsu H, Goeddel DV, Karin M. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87:565-576.
80. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W. 1990. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61:351-359.
81. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490.
82. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. 1997. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385:540-544.
83. Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J, Anel A. 1998. Involvement of APO2 ligand/ TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 28:2714-2725.
84. Mason AT, McVicar DW, Smith CA, Young HA, Ware CF, Ortaldo JR. 1995. Regulation of NK cells through the 80-kDa TNFR (CD120b). J Leukoc Biol 58:249-255.
85. Miura M, Friedlander RM, Yuan J. 1995. Tumor necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. Proc Natl Acad Sci USA 92:8318-8322.
86. Monastra G, Cabrelle A, Zambon A, Rosato A, Macino B, Collavo D, Zanovello P. 1996. Membrane form of TNF alpha induces both cell lysis and apoptosis in susceptible target cells. Cell Immunol 171: 102-110.
87. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-827.
88. Nagata S, Golstein P. 1995. The Fas death factor. Science 267:1449-1456.
89. Nagata S. 1997. Apoptosis by death factor. Cell 88:355-365.
90. Nishio M, Spielman J, Lee RK, Nelson DL, Podack ER. 1996. CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis. J Immunol 157:4347-4353.
91. Old LJ. 1985. Tumor necrosis factor (TNF). Science 230:630-632.
92. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. 1996. Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184:1397-1411.
93. Pasparakis M, Alexopoulou L, Grell M, Pfizenmaier K, Bluethmann H, Kollias G. 1997. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc Natl Acad Sci USA 94:6319-6323.
94. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. 1990. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251-258.
95. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA. 1998a. An essential role for ectodomain shedding in mammalian development. Science 282:1281-1284.
96. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM. 1998b. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160:943-952.
97. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467.
98. Ponton A, Clement MV, Stamenkovic I. 1996. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J Biol Chem 271:8991-8995.
99. Qian JH, Titus JA, Andrew SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM. 1991. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol146:3250-3256.
100. Ranges GE, Figari IS, Espevik T, Palladino MA Jr. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 166: 991-998.
101. + cytotoxic T lymphocyte-mediated lysis. J Immunol 150:4303-4314.
102. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. 1997. Identification and characterization of an IkappaB kinase. Cell 90: 373-383.
103. Reinhard C, Shamoon B, Shyamala V, Williams LT. 1997. Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J 16:1080-1092.
104. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M. 1998. Perforin and IFN-γ are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160:5309-5313.
105. Ross ME, Caligiuri MA. 1997. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89:910-918.
106. Roth AD, Hornicek FJ, Gerstner CG, Kirkwood JM. 1991. Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol 86: 163-172.
107. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802.
108. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. 1995. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-1252.
109. Santis AG, Campanero MR, Alonso JL, Sanchez-Madrid F. 1992. Regulation of tumor necrosis factor (TNF)-α synthesis and TNF receptors expression in T lymphocytes through the CD2 activation pathway. Eur J Immunol 22:3155-3160.
110. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. 1999. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18:3044-3053.
111. Saoulli K, Lee SY, Cannons JL, Yeh WC, Santana A, Goldstein MD, Bangia N, DeBenedette MA, Mak TW, Choi Y, Watts TH. 1998. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 187:1849-1862.
112. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lentz R, Raab H, et al. 1990. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61:361-370.
113. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med187:1205-1213.
114. Schreiber M, Sedger L, McFadden G. 1997. Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol 71:2171-2181.
115. Schulze-Osthoff K, Krammer PH, and Droge W. 1994. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 13:4587-4596.
116. Sean Riminton D, Korner H, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. 1998. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J Exp Med 187:1517-1528.
117. Sedger L, McFadden G. 1996. M-T2: a poxvirus TNF receptor homologue with dual activities. Immunol. Cell Biol 74:538-545.
118. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. 1995. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 181:607-617.
119. Shisler J, Yang C, Walter B, Ware CF, Gooding LR. 1997. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol 71:8299-8306.
120. Shu HB, Halpin DR, Goeddel DV. 1997 Casper is a FADD-and caspase-related inducer of apoptosis. Immunity 6:715-723.
121. Singer GG, Abbas AK. 1994. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365-371.
122. + cytotoxic T lymphocytes. Eur J Immunol 28:4162-4169.
123. Smyth MJ, Norihisa Y, Ortaldo JR. 1992. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. J Immunol 148:55-62.
124. + cytotoxic T lymphocytes. J Virol 72:5948-5954.
125. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. 1999. Perform is a major contributor to NK cell control of tumor metastasis. J Immunol 162:6658-6662.
126. Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M. 1997. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 94:9792-9796.
127. Soto U, Das BC, Lengert M, Finzer P, zur Hausen H, Rosl F. 1999. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-α mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 18:3187-3198.
128. Speiser DE, Sebzda E, Ohteki T, Bachmann MF, Pfeffer K, Mak TW, Ohashi PS. 1996. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 26:3055-3060.
129. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. 1995. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81:513-523.
130. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. 1994. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77:727-736.
131. Sytwu HK, Liblau RS, McDevitt HO. 1996. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5:17-30.
132. Tan S, Sagara Y, Liu Y, Maher P, Schubert D. 1998. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141:1423-1432.
133. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. 1996. Fas ligand in human serum. Nat Med 2:317-322.
134. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88:9292-9296.
135. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino MA Jr. 1993a. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 151:4637-4641.
136. Tartaglia LA, Rothe M, Hu YF, Goeddel DV. 1993b. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 73:213-216.
137. Tewari M, Dixit VM. 1995. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 270:3255-3260.
138. Thomas WD, Hersey P. 1998. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 161: 2195-2200.
139. +, class II MHC-restricted cytotoxic T cells. Immunology 71:208-212.
140. Tucek-Szabo CL, Andjelic S, Lacy E, Elkon KB, Nikolic-Zugic J. 1996. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor. J Immunol 156:192-200.
141. Tschopp J, Irmler M, Thome M. 1998. Inhibition of Fas signals by FLIPs. Curr Opin Immunol 10:552-558.
142. Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. 1996. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 93:4974-4978.
143. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. 1998. Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol 8:107-111.
144. van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 25:3514-3516.
145. Vercammen D, Bayaert R, Deneckar G, Goossens V, Van Loo G, Declercq W, Grooten J, Fiers W, Vandenabeele P. 1998. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 187:1477-1485.
146. Wang J, Stohlman SA, Dennert G. 1994. TCR cross-linking induces CTL death via internal action of TNF. J Immunol 152:3824-3832.
147. Wong GH, Elwell JH, Oberley LW, Goeddel DV. 1989. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58:923-931.
148. Yang X, Khosravi-Far R, Chang HY, Baltimore D. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89: 1067-1076.
149. Yang Y, Chang JF, Parnes JR, Fathman CG. 1998. T cell receptor (TCR) engagement leads to activation-induced splicing of tumor necrosis factor (TNF) nuclear pre-mRNA. J Exp Med 188:247-254.
150. + human cytotoxic T-cell clones. Blood 81:1527-1534.
151. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188:2375-2380.
152. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348-351.
153. Zhou T, Edwards CK 3rd, Yang P, Wang Z, Bluethmann H, Mountz JD. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 156:2661-2665.
154. Zimmerman RJ, Chan A, Leadon SA. 1989a. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 49:1644-1648.
155. Zimmerman RJ, Marafino BJ Jr, Chan A, Landre P, Winkelhake JL. 1989b. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action. J Immunol 142:1405-1409.